Association of a Variant of CNR1 Gene Encoding Cannabinoid Receptor 1 With Gilles de la Tourette Syndrome

被引:13
|
作者
Szejko, Natalia [1 ,2 ]
Fichna, Jakub Piotr [3 ]
Safranow, Krzysztof [4 ]
Dziuba, Tomasz [1 ]
Zekanowski, Cezary [3 ]
Janik, Piotr [1 ]
机构
[1] Med Univ Warsaw, Dept Neurol, Warsaw, Poland
[2] Med Univ Warsaw, Dept Bioeth, Warsaw, Poland
[3] Polish Acad Sci, Mossakowski Med Res Ctr, Dept Neurodegenerat Disorders, Lab Neurogenet, Warsaw, Poland
[4] Pomeranian Med Univ, Dept Biochem & Med Chem, Szczecin, Poland
关键词
Gilles de la Tourette syndrome; endocannabinoids; association study; CNR1; gene; CB1cannabinoid receptor 1; DELTA(9)-TETRAHYDROCANNABINOL THC; ENDOCANNABINOID SYSTEM; POLYMORPHISMS; DISORDER; THERAPY; OBESITY; IMPULSIVITY; IMPACT; INDEX; RISK;
D O I
10.3389/fgene.2020.00125
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Background Gilles de la Tourette syndrome (GTS) is a neuropsychiatric disorder of unknown etiology, although a major role of genetic factors has been established. Cannabis-based medicines may alleviate GTS-associated tics and variants of CNR1 gene encoding central cannabinoid receptor (CB1) are believed to be a risk factor for the development of some neurodevelopmental diseases. Our aim was to test the association of selected CNR1 gene variants with GTS. Material and Methods The cohort of GTS cases comprised 262 unrelated patients aged 3-53 years (mean age: 18.3 +/- 9.1 years; 204 males (77.9%), 126 (48.1%) adults defined as >= 18 years). As a control group we enrolled 279 unrelated, ethnically and gender matched individuals with no diagnosed mental, neurological or general disorder, aged 13-54 years (mean age: 22.5 +/- 3.0 years; 200 males, (74.1%). Both study and control groups were selected from Polish population, which is ethnically homogenous subgroup of Caucasian population. Four single nucleotide polymorphisms (SNPs) in CNR1 were selected: rs2023239, rs2180619, rs806379, and rs1049353 based on minor allele frequency in general population >15%. These variants were genotyped using a real-time quantitative polymerase chain reaction system (TaqMan SNP genotyping assay). Results We found significant association of GTS clinical phenotype with rs2023239 variant. Minor allele C and CT+CC genotypes were found significantly more often in GTS patients compared to controls (17.4 vs 11.1%, p=0.003 and 32.8 vs 20.4%, p=0.001, respectively), and the difference remained significant after correction for multiple testing. C allele of rs2023239 polymorphism of the CNR1 gene was associated with the occurrence of tics. There were no statistically significant associations for rs806379, rs1049353 or rs2180619 variants. Conclusion Our findings suggest that C allele of rs2023239 polymorphism of the CNR1 gene is a risk factor of GTS in Polish population. The variant can be potentially associated with abnormal endocannabinoid transmission, which is suspected to be one of the causes of GTS.
引用
收藏
页数:9
相关论文
共 50 条
  • [21] Lack of Association between (AAT)n Polymorphism of the CNR1 Gene Encoding the Cannabinoid Receptor (CB1) and Patient's Quality of Life
    Machoy-Mokrzynska, Anna
    Rac, Monika
    Jurewicz, Alina
    Dziedziejko, Violetta
    Safranow, Krzysztof
    Kurzawski, Mateusz
    Boron, Agnieszka
    Stefaniak, Arkadiusz
    Leznicka, Katarzyna
    Bohatyrewicz, Andrzej
    Bialecka, Monika
    GENES, 2022, 13 (11)
  • [22] G1359A polymorphism of the cannabinoid receptor gene (CNR1) and clinical results of biliopancreatic diversion
    de Luis, D. A.
    Pacheco, D.
    Aller, R.
    Gonzalez Sagrado, M.
    Conde, R.
    Izaola, O.
    Cuellar, L.
    Terroba, M. C.
    Martin, T.
    Ventosa, M.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2010, 14 (03) : 197 - 201
  • [23] Detection of Significant Association Between Variants in Cannabinoid Receptor 1 Gene (CNR1) and Personality in African-American Population
    Yao, Yinghao
    Xu, Yi
    Zhao, Junsheng
    Ma, Yunlong
    Su, Kunkai
    Yuan, Wenji
    Ma, Jennie Z.
    Payne, Thomas J.
    Li, Ming D.
    FRONTIERS IN GENETICS, 2018, 9
  • [24] CNR1 Gene and Risk of the Metabolic Syndrome in Patients With Schizophrenia
    Yu, Weiping
    De Hert, Marc
    Moons, Tim
    Claes, Stephan J.
    Correll, Christoph U.
    van Winkel, Ruud
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2013, 33 (02) : 186 - 192
  • [25] A common variation in the cannabinoid 1 receptor (CNR1) gene is associated with pre-eclampsia in the Central European population
    Bienertova-Vasku, Julie
    Bienert, Petr
    Dostalova, Zuzana
    Chovanec, Josef
    Vasku, Anna
    Vasku, Vladimir
    EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 2011, 155 (01) : 19 - 22
  • [26] Single Nucleotide Change in the Cannabinoid Receptor-1 (CNR1) Gene in Colorectal Cancer Outcome
    Bedoya, Fernando
    Rubio, Juan C.
    Morales-Gutierrez, Carlos
    Abad-Barahona, Alfredo
    Lora Pablos, David
    Meneu, Juan C.
    Moreno-Gonzalez, Enrique
    Enriquez de Salamanca, Rafael
    Vegh, Irene
    ONCOLOGY, 2009, 76 (06) : 435 - 441
  • [27] Roles of G1359A polymorphism of the cannabinoid receptor gene (CNR1) on weight loss and adipocytokines after a hypocaloric diet
    De Luis, D. A.
    Gonzalez Sagrado, M.
    Aller, R.
    Conde, R.
    Izaola, O.
    de la Fuente, B.
    Primo, D.
    NUTRICION HOSPITALARIA, 2011, 26 (02) : 317 - 322
  • [28] Depression in Parkinson's disease is related to a genetic polymorphism of the cannabinoid receptor gene (CNR1)
    Barrero, FJ
    Ampuero, I
    Morales, B
    Vives, F
    del Castillo, JDL
    Hoenicka, J
    Yébenes, JG
    PHARMACOGENOMICS JOURNAL, 2005, 5 (02): : 135 - 141
  • [29] No association of CNR1 gene variations with susceptibility to schizophrenia
    Seifert, Juergen
    Ossege, Sebastian
    Emrich, Hinderk M.
    Schneider, Udo
    Stuhrmann, Manfred
    NEUROSCIENCE LETTERS, 2007, 426 (01) : 29 - 33
  • [30] Depression in Parkinson's disease is related to a genetic polymorphism of the cannabinoid receptor gene (CNR1)
    F J Barrero
    I Ampuero
    B Morales
    F Vives
    J de Dios Luna del Castillo
    J Hoenicka
    J García Yébenes
    The Pharmacogenomics Journal, 2005, 5 : 135 - 141